WallStSmart
DWTX

Dogwood Therapeutics, Inc.

NASDAQ: DWTX · HEALTHCARE · BIOTECHNOLOGY

$1.86
-10.71% today

Updated 2026-06-05

Market cap
$50.44M
P/E ratio
1.28
P/S ratio
EPS (TTM)
$1.17
Dividend yield
52W range
$1 – $10
Volume
0.1M

Dogwood Therapeutics, Inc. (DWTX) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20182019202020212022202320242025
Revenue$0.00$0.00$0.00$0.00$0.00$0.00
Revenue growth (YoY)
Cost of revenue$12177.00
Gross profit$-12177.00
Gross margin
R&D$854109.00$800620.00$194013.00$10.80M$8.07M$1.73M$3.53M$21.87M
SG&A$1.11M$1.38M$9.81M$4.85M$4.25M$3.72M$8.70M$6.10M
Operating income$-1.96M$-2.18M$-10.01M$-15.64M$-12.32M$-5.45M$-12.23M$-27.97M
Operating margin
EBITDA$-1.96M$-2.18M$-10.01M$-15.64M$-12.32M$-5.45M$-12.25M$-27.97M
EBITDA margin
EBIT$-1.96M$-2.18M$-10.01M$-15.64M$-12.32M$-5.45M$-12.26M$-27.97M
Interest expense$152103.00$295128.00$384222.00$92192.00
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-2.11M$-2.47M$-10.35M$-15.96M$-12.25M$-5.30M$-12.35M$-34.26M
Net income growth (YoY)-17.0%-318.3%-54.3%+23.3%+56.8%-133.2%-177.4%
Profit margin

Frequently asked questions

How much free cash flow does DWTX generate?

DWTX produced $-15.62M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is DWTX's balance sheet healthy?

DWTX holds $6.52M in cash and equivalents against — in long-term debt, on $74.90M of shareholder equity. That debt is best read against the cash flow the business throws off each year.